{
    "nctId": "NCT01644669",
    "briefTitle": "Safety and Efficacy Study of the Xoft\u00ae Axxent\u00ae eBx\u00ae IORT System\u00ae",
    "officialTitle": "A Safety and Efficacy Study of Intra-Operative Radiation Therapy (IORT) Using the Xoft\u00ae Axxent\u00ae eBx\u00ae System\u00ae at the Time of Breast Conservation Surgery for Early Stage Breast Cancer",
    "overallStatus": "ACTIVE_NOT_RECRUITING",
    "conditions": "Invasive Ductal Carcinoma, Ductal Carcinoma in Situ",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 1200,
    "primaryOutcomeMeasure": "Assess the rate of ipsilateral breast tumor recurrence (IBTR) at 5 years",
    "eligibilityCriteria": "Inclusion Criteria:\n\n1. Subject must have provided written Informed Consent\n2. Subject must have biopsy-proven invasive ductal carcinoma or ductal carcinoma in situ of the breast\n3. Subject must be female \u2265 40 years of age\n4. Subject's tumor(s) must be \\< 3.0 cm in greatest diameter by pre-operative assessment\n5. Subject's tumor(s) must meet AJCC Tumor Classification: Tis, T1 or T2 (\\< 3 cm), N0, M0\n6. Subject presenting with bilateral breast cancer may be enrolled if BOTH cancers meet all of the inclusion and none of the exclusion criteria\n7. Women of child-bearing potential must have a negative pregnancy test within one week of IORT treatment\n8. Women of child-bearing potential must agree to use adequate contraceptive precautions (defined as oral contraceptives, intrauterine devices, surgical contraceptives or a combination of condom and spermicide) from the time of negative pregnancy test through completion of the radiation treatment period\n\nExclusion Criteria:\n\n1. Subject is pregnant or nursing\n2. Subject has significant auto-immune disease\n3. Subject has a pacemaker present in the field of radiation or quadrant of the breast cancer\n4. Subject has biopsy-proven multifocal breast cancer\n5. Subject has multi-centric breast cancer\n6. Subject has known lympho-vascular invasion\n7. Subject has invasive lobular cancer\n8. Subject has undergone neo-adjuvant chemotherapy or neo-adjuvant endocrine therapy for current breast cancer\n9. Subject has a history of recurrent breast cancer in the ipsilateral breast\n10. Subject has had previous radiation exposure of the involved breast\n11. Subject has BRCA 1 or 2 mutations. Note: Testing will only be required for Subjects presenting with bilateral breast cancer; testing is not required for unilateral cancers\n12. Subject has contraindications for radiation\n13. Subject considered by the Investigator to be high-risk for breast conservation surgery and/or intra-operative radiation therapy\n14. Subject has participated in any other clinical investigation that is likely to confound study results or affect study outcome either at the time of IORT or for 3 months prior to IORT.",
    "sex": "FEMALE",
    "minimumAge": "40 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}